257 related articles for article (PubMed ID: 15031566)
1. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
[TBL] [Abstract][Full Text] [Related]
2. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma.
Chuchalin AG; Manjra AI; Rozinova NN; Skopková O; Cioppa GD; Till D; Kaiser G; Fashola T; Kottakis J
J Aerosol Med; 2005; 18(1):63-73. PubMed ID: 15741775
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
LaForce C; Prenner BM; Andriano K; Lavecchia C; Yegen U
J Asthma; 2005 Mar; 42(2):101-6. PubMed ID: 15871441
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[TBL] [Abstract][Full Text] [Related]
5. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
7. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
Pleskow W; LaForce CF; Yegen U; Matos D; Della Cioppa G
J Asthma; 2003; 40(5):505-14. PubMed ID: 14529100
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[TBL] [Abstract][Full Text] [Related]
10. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling.
Eliraz A; Ramirez-Rivera A; Ferranti P; Holzer R; García JM; Turcotte C; Rapatz G; Pfister P; Overend T; Kottakis J
Int J Clin Pract; 2001 Apr; 55(3):164-70. PubMed ID: 11351769
[TBL] [Abstract][Full Text] [Related]
11. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
Bensch G; Lapidus RJ; Levine BE; Lumry W; Yegen U; Kiselev P; Della Cioppa G
Ann Allergy Asthma Immunol; 2001 Jan; 86(1):19-27. PubMed ID: 11206232
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
[TBL] [Abstract][Full Text] [Related]
13. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
Miller CJ; Senn S; Mezzanotte WS
Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma.
Otto-Knapp R; Conrad F; Hösch S; Metzenauer P; Maus J; Noga O; Petzold U; Kunkel G
Pulm Pharmacol Ther; 2008; 21(1):47-53. PubMed ID: 17475527
[TBL] [Abstract][Full Text] [Related]
20. Nebulized formoterol fumarate: Dose selection and pharmacokinetics.
Gross NJ; Kerwin E; Levine B; Kim KT; Denis-Mize K; Hamzavi M; Carpenter M; Rinehart M
Pulm Pharmacol Ther; 2008 Oct; 21(5):818-23. PubMed ID: 18655841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
